JumpCan

Recently, the final review results of the Jiangsu Association of Chinese Medicine, the Jiangsu Association of Integrative Medicine, and the Jiangsu Association of Acupuncture-Moxibustion’s TCM Science and Technology Awards for 2024–2025 were publicized. The project "Key Technological Innovation and Application of Pediatric TCM Re-evaluation, Re-discovery and Re-innovation," jointly undertaken by JumpCan Pharmaceutical in collaboration with China Pharmaceutical University, Jiangsu Province Academy of Traditional Chinese medicine, and other partners, was awarded the First Prize of the Jiangsu TCM Science and Technology Award, further recognizing the company's innovation and R&D capabilities.

The Jiangsu TCM Science and Technology Award is an award approved by the Jiangsu Provincial Department of Science and Technology, representing the highest level of technology in the TCM industry in Jiangsu Province. The award is jointly sponsored by the Jiangsu Association of Chinese Medicine, Jiangsu Association of Integrative Medicine, and the Jiangsu Association of Acupuncture-Moxibustion. It honors collectives and individuals who have achieved excellent results in the academic fields of TCM (and integrative medicine) in Jiangsu, with the aim of fully mobilizing the enthusiasm and creativity of TCM science and technology workers, further flourishing TCM academics, and promoting the development of TCM science and technology.

The project "Key Technological Innovation and Application of Pediatric TCM Re-evaluation, Re-discovery, and Re-innovation" excavates the clinical potential of traditional formulas through re-evaluation, clarifies the pharmacologically active substances and mechanisms of action through re-discovery, and ultimately achieves dosage form optimization and quality upgrading through re-innovation. This award not only represents another certification of the company's innovation capabilities, but also highlights its commitment to safeguarding children's health.

As one of the leading pharmaceutical enterprises in China's pediatric pharmaceutical sector, JumpCan Pharmaceutical has long focused on children's health needs, driving continuous R&D investment and technological innovation through deep industry-academia-research integration. Addressing clinical pain points such as poor compliance medication and low dosing precision in pediatric medication, the company is committed to achieving optimization of drug dosage forms and upgrading of quality control systems, continuously innovating and developing pediatric drugs in line with clinical needs, steadily expanding its pediatric product portfolio, and building a children's drug product matrix covering respiratory, gastrointestinal, dermatology, and other areas to meet children's diverse medication needs.

Going forward, JumpCan Pharmaceutical will continue to place scientific and technological innovation at the strategic level, focus on building a medium- and long-term tiered product matrix, with pediatrics, respiratory, gastrointestinal, and dermatology as the core areas, and continuously deepen the R&D of innovative drugs with high technological barriers and high clinical value. The company will accelerate the translation of scientific and technological achievements into clinical applications, continuously bring richer innovative treatment options to patients, precisely meet differentiated medication needs, and contribute JumpCan's strength to the Healthy China strategy.